Refine
Has Fulltext
- yes (7)
Is part of the Bibliography
- yes (7)
Document Type
- Journal article (7)
Language
- English (7)
Keywords
- CNS cancer (1)
- DC vaccination (1)
- IL-10 (1)
- MDSC (1)
- TLR agonists (1)
- acute (1)
- acute graft-versus-host disease (1)
- alloreactive T cells (1)
- anaplastic medulloblastoma (1)
- animal model (1)
- brain tumor (1)
- cancer (1)
- cancer stem cells (1)
- cancer vaccines (1)
- cardiogenic (1)
- children (1)
- clinical trial (1)
- dendritic cells (1)
- extracorporeal membrane oxygenation (1)
- group 3 (1)
- immunotherapy (1)
- leukemia (1)
- macrophages (1)
- malignant glioma (1)
- monocyte-derived DC (1)
- mouse models (1)
- myeloid (1)
- orthotopic xenograft (1)
- paediatric cancer (1)
- pediatrics (1)
- prediction (1)
- prostaglandin E2 (1)
- regulatory dendritic cells (1)
- septic (1)
- shock (1)
- transplantation (1)
- tumor-specific CD8+ T cells (1)
Institute
- Kinderklinik und Poliklinik (7)
- Medizinische Klinik und Poliklinik II (4)
- Neurochirurgische Klinik und Poliklinik (2)
- Pathologisches Institut (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Klinik für Anaesthesiologie (bis 2003) (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (1)
Acute graft-versus-host disease (aGvHD) is a severe and often life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT). AGvHD is mediated by alloreactive donor T-cells targeting predominantly the gastrointestinal tract, liver, and skin. Recent work in mice and patients undergoing allo-HCT showed that alloreactive T-cells can be identified by the expression of α4β7 integrin on T-cells even before manifestation of an aGvHD. Here, we investigated whether the detection of a combination of the expression of T-cell surface markers on peripheral blood (PB) CD8\(^+\) T-cells would improve the ability to predict aGvHD. To this end, we employed two independent preclinical models of minor histocompatibility antigen mismatched allo-HCT following myeloablative conditioning. Expression profiles of integrins, selectins, chemokine receptors, and activation markers of PB donor T-cells were measured with multiparameter flow cytometry at multiple time points before the onset of clinical aGvHD symptoms. In both allo-HCT models, we demonstrated a significant upregulation of α4β7 integrin, CD162E, CD162P, and conversely, a downregulation of CD62L on donor T-cells, which could be correlated with the development of aGvHD. Other surface markers, such as CD25, CD69, and CC-chemokine receptors were not found to be predictive markers. Based on these preclinical data from mouse models, we propose a surface marker panel on peripheral blood T-cells after allo-HCT combining α4β7 integrin with CD62L, CD162E, and CD162P (cutaneous lymphocyte antigens, CLA, in humans) to identify patients at risk for developing aGvHD early after allo-HCT.